Live Breaking News & Updates on Curadev pharma

Stay informed with the latest breaking news from Curadev pharma on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Curadev pharma and stay connected to the pulse of your community

Curadev's Differentiated Next Generation STING Agonist CRD3874-SI

(This story has not been edited by THE WEEK and is auto-generated from a PTI

San-diego , California , United-states , India , Boston , Massachusetts , Ciara-kelly , Curadev-pharma , Monali-banerjee , Prnewswire-curadev , Society-of-immunotherapy-cancer , Memorial-sloan-kettering-cancer-center

Rupee rises 18 p to 81.93 against US dollar in early trade

Mumbai, April 13: The Indian rupee rose 18 paise to Rs 81.94 against the US dollar on Thursday morning.

Mumbai , Maharashtra , India , Curadev-pharma , Financial-services , Institutional-investors , Corporate-social-responsibility , Rupee-rises-18p-to-81-93-against-us-dollar-in-early-trade , Rupee , Ises , Ollar , Arly

Curadev Pharma's CSR Corporate Social Responsibility Projects – An Update

(This story has not been edited by THE WEEK and is auto-generated from a PTI

India , New-delhi , Delhi , Madhya-pradesh , Tamil-nadu , Chhattisgarh , Midnapore , West-bengal , Chennai , Uttar-pradesh , Guindy , Curadev-pharma

Curadev Pharma's CSR (Corporate Social Responsibility) Projects

Noida (Uttar Pradesh) [India], April 13 (ANI/PRNewswire): In the area of CSR - Corporate Social Responsibility - the motivating force behind Curadev's activities is the awareness that businesses have a social responsibility to the communities they serve.

Uttar-pradesh , India , Madhya-pradesh , Tamil-nadu , New-delhi , Delhi , Guindy , Chennai , Chhattisgarh , Midnapore , West-bengal , Noida-uttar-pradesh

Curadev Pharma announces the formation of its Clinical Advisory Group

Noida (Uttar Pradesh) [India], January 4 (ANI/PRNewswire): Curadev Pharma has created a Clinical Advisory Group (CAG) comprising eminent oncologists to provide guidance in the design and execution of immune-oncology clinical trials with CRD3874, its lead non-nucleoside, allosteric small molecule STING agonist

United-states , Mumbai , Maharashtra , India , Bengaluru , Karnataka , United-kingdom , Navin-khattry , Jacob-sands , Noida-uttar-pradesh , Arjun-surya , Curadev-pharma

Curadev Pharma announces the formation of its Clinical Advisory Group - Jammu Kashmir Latest News | Tourism

NOIDA, UP, Jan 4: Curadev Pharma has created a Clinical Advisory Group (CAG) comprising eminent oncologists to provide guidance in the design and execution of immune-oncology clinical trials with CRD3874, its lead non-nucleoside, allosteric small molecule STING agonist. Curadev recently received permission from the US FDA to commence FIH trials with systemically administered CRD3874 in patients with advanced/metastatic solid cancers. Dr Arjun Surya, CEO and CSO of Curadev said that, “We are honored to work with such an esteemed group […]

United-states , Mumbai , Maharashtra , India , Bengaluru , Karnataka , United-kingdom , Navin-khattry , Jacob-sands , Arjun-surya , Curadev-pharma , K-govind-babu

Curadev Pharma announces the formation of its Clinical Advisory Group

/PRNewswire/ -- Curadev has created a Clinical Advisory Group (CAG) comprising of eminent oncologists to provide guidance in the design and execution of...

Mumbai , Maharashtra , India , United-states , United-kingdom , Harvard-university , Massachusetts , Dana-farber-cancer-institute , Boston , Bengaluru , Karnataka , Navin-khattry

Curadev Pharma announces the formation of its Clinical Advisory Group

/PRNewswire/ -- Curadev has created a Clinical Advisory Group (CAG) comprising of eminent oncologists to provide guidance in the design and execution of...

Mumbai , Maharashtra , India , United-states , United-kingdom , Harvard-university , Massachusetts , Dana-farber-cancer-institute , Boston , Bengaluru , Karnataka , Navin-khattry

Curadev Pharma receives FDA 'Study May Proceed' Letter for its Investigational New Drug Application of CRD3874

Boston (Massachusetts) [US]/ Noida (Uttar Pradesh) [India], December 6 (ANI/PRNewswire): Curadev Pharma, a small molecule drug discovery and development company focused on the generation of novel therapeutics for the treatment of intractable diseases such as cancer has received a Study May Proceed letter from the United States Food and Drug Administration (FDA) to begin a Phase 1 study of its lead STING agonist CRD3874 in advanced/metastatic solid cancers. The study will be performed at a leading US cancer center. Successful clearance of tumors by the immune system requires the action of Type I IFNs. When activated in cells of the tumor microenvironment and lymph nodes, the immune adaptor protein STING coordinates proinflammatory immune responses by generating Type I IFNs and NF-kB activated cytokines. The human STING gene is polymorphic, with five major variants covering 98.8% of the population. CRD3874 is a potent allosteric activator of all major human STING variants covering 98.8% of the population and is differentiated from the CDN class of STING agonists. CRD3874 displays strong T cell dependent anti-tumor activity when dosed through either the IV or IT routes in a range of syngeneic tumor models as a single agent or in combination with checkpoint inhibitors. As would be anticipated for an immune-modulated mechanism of action, mice that experienced complete tumor regression on treatment were refractory to challenge from re-engrafted tumor cells. "Immune evasion is an absolute requirement for the establishment of cancers. The systemic activation of STING by intravenous infusion of CRD3874-SI in patients with cancer is an attempt to re-activate dormant or disrupted immune mechanisms of tumor clearance," says Dr Arjun Surya, CEO & CSO of Curadev. Curadev is a small molecule drug discovery and development biotech with an exciting portfolio of research programs that have yielded patent protected drug candidates. Founded in 2010, Curadev has created a premier translational research organization known for prescient target selection and high quality, data-driven program execution. Programs at Curadev seek to ameliorate disease by translating cutting edge discoveries into new medicines. To know more about Curadev, visit our website www.curadev.in. For enquiries: Manish Tandon, Co-Founder & CFO business@curadev.in This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)

United-states , Massachusetts , Noida-uttar-pradesh , Arjun-surya , Manish-tandon , Curadev-pharma , Drug-administration , Uttar-pradesh , Study-may-proceed , United-states-food , Boston-massachusetts-us-noida-uttar-pradesh-india- , Ecember-6-ani-prnewswire-curadev-pharma

European Patent Office upholds Curadev's cyclodextrin patent for new composition of matter

/PRNewswire/ -- Sulphobutyl ether β-cyclodextrin (SBE-β-CD) is used as an excipient to improve the solubility and stability of a range of active pharmaceutical...

Steve-wicks , Manish-tandon , Curadev-pharma , Prnewswire-sulphobutyl , Anton-hutter , Venner-shipley , Curadev-pharma-private , European-patent-office , Ligand-pharmaceuticals , University-of-greenwich , Professor-steve-wicks , Lead-counsel